As of November 10, 2026, Xenon Pharmaceuticals Inc. is a publicly traded company (Nasdaq: XENE); its largest reported holder is Fidelity (FMR), with 11.5% on Schedule 13G/A of November 5, 2026, then T. Rowe Price (8.2%). The largest insider holding is Ian Mortimer, the chief executive and president, with 64,223 shares (0.07% of shares outstanding), per Form 4 of October 1, 2026 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Xenon Pharmaceuticals Inc.? See the free Snapshot first.
Free to see. No signup.
Is Xenon Pharmaceuticals Inc. a real, registered company?
- Xenon Pharmaceuticals Inc. files with the SEC under CIK 1582313 (its SEC filings).
- Its shares are listed under the ticker XENE on Nasdaq (SEC company record).
- Incorporated in A1, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under XENON PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-11-06).
Who are Xenon Pharmaceuticals Inc.'s owners and officers?
Xenon Pharmaceuticals Inc.: industry Pharmaceutical Preparations (Schedule 13G, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 8.2% |
| Schedule 13G/A, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 10.3% |
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 11.5% |
| Schedule 13G/A, 2026-08-13 | Wellington Management Group LLP | 1.5% |
| Schedule 13G/A, 2026-08-07 | Fmr LLC | 10.3% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 9.9% |
| Schedule 13G/A, 2026-05-15 | Avoro Capital Advisors LLC | 6.26% |
| Schedule 13G/A, 2026-05-15 | Driehaus Capital Management LLC | 4.87% |
| Schedule 13G/A, 2026-05-15 | Janus Henderson Group PLC | 4.5% |
| Schedule 13G, 2026-02-10 | Wellington Management Group LLP | 6.2% |
| Schedule 13G, 2025-11-14 | Janus Henderson Group PLC | 5.1% |
| Schedule 13G/A, 2025-08-12 | Wellington Management Group LLP | 2.8% |
Questions about who owns Xenon Pharmaceuticals Inc.
Who owns Xenon Pharmaceuticals Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Xenon Pharmaceuticals Inc.: Fmr LLC (11.5%, Schedule 13G/A, filed 2026-11-05), T. Rowe Price Investment Management, Inc. (8.2%, Schedule 13G, filed 2026-11-06) and Avoro Capital Advisors LLC (6.26%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of Xenon Pharmaceuticals Inc.?
By the share each holder's latest filing reports, the largest holders of Xenon Pharmaceuticals Inc. on this page are Fmr LLC (11.5%), T. Rowe Price Investment Management, Inc. (8.2%) and Avoro Capital Advisors LLC (6.26%).
When did Fmr LLC buy into Xenon Pharmaceuticals Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G/A, filed 2026-08-06, reporting 9.9%; its latest, Schedule 13G/A filed 2026-11-05, reports 11.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Xenon Pharmaceuticals Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Xenon Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xenon Pharmaceuticals Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Xenon Pharmaceuticals Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 64,223 shares (0.07% of shares outstanding), 49,923 held directly and 14,300 indirectly (Form 4, 2026-10-01).
- , a director: 31,373 shares (0.03% of shares outstanding) (Form 4, 2026-09-03).
- , a director: 29,798 shares (0.03% of shares outstanding), 24,896 held directly and 4,902 indirectly (Form 4, 2026-06-08).
- , the chief financial officer: 22,500 shares (0.02% of shares outstanding) (Form 4, 2026-10-16).
- , the chief legal officer: 7,301 shares (0.01% of shares outstanding) (Form 4, 2026-03-13).
Shares outstanding: 98,284,734 as of 2026-11-05, from the company's latest SEC cover page.
How much has Xenon Pharmaceuticals Inc. raised?
No fundraising or offering filing from Xenon Pharmaceuticals Inc. is on file with us.
Keep reading
More on Xenon Pharmaceuticals Inc. and the records around it.
Xenon Pharmaceuticals Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/xenon-pharmaceuticals